JUN and neoplasm: Using a model of tonic CAR signaling leading to T-cell exhaustion, retroviral overexpression of c-Jun, an AP-1 factor, enhanced CAR T-cell expansion and functionality, decreased terminal effector differentiation, and improved antitumor potency in five different in vivo tumor models (123).